



Prior Authorization Approval Criteria
Department of Pharmacy Services

Generic Name: carbidopa, levodopa, and entacapone
Brand Name: Stalevo
Medication Class: dopamine precursor and dopamine agonists
FDA Approved Uses: Parkinson's disease
Usual Doses: 1-8 tablets/day. Max daily dose is 8 tablets of Stalevo per day
Duration of Therapy: Indefinite

Criteria for use: *(bullet points below are all inclusive unless otherwise noted)*

- Clinically diagnosed Parkinson's disease
- Failed / Intolerant to carbidopa/ levodopa
- Failed / Intolerant to entacapone
- Inability to take two medications
- Must be receiving 600mg or less of levodopa
- Must be experiencing "wearing off" symptoms

Contraindications:

- Hypersensitivity to any component (carbidopa, levodopa, or entacapone) of the drug or its excipients.
- Concomitant use of MAOIs
- Narrow angle glaucoma
- Undiagnosed skin lesions or history of melanoma.

Not approved if:

- Patient does not have Parkinson's disease
- Patient has not tried each individual component
- Experiencing dyskinesias
- Patient is **not** experiencing "wearing off" symptoms
- Patient has any contraindications to the use of Stalevo